ArticleJournal of addiction medicine2026
Contingency Management for Stimulant-Opioid Co-Use: A Systematic Review and Meta-Analysis.
Article in Journal of addiction medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveWe conducted a meta-analysis (PROSPERO CRD420251000204) examining treatment outcomes associated with contingency management for individuals with stimulant-opioid co-use.
methodsWe searched Cochrane Library, Embase, PubMed, PsycINFO, and Web of Science through March 2026. Randomized controlled trials evaluating contingency management among individuals with past-year stimulant-opioid co-use were eligible. Outcomes included the longest duration of continuous, simultaneous abstinence from stimulants and opioids during treatment, the percentage of combined stimulant-opioid-negative urine toxicology samples, and treatment retention. Data were extracted following PRISMA guidelines, and random-effects meta-analyses were performed.
resultsTwenty-six trials (N=2356) were included. Across studies, cocaine was the stimulant of interest and heroin the primary opioid; fentanyl exposure was not reported in any trial. Contingency management significantly increased the longest duration of continuous abstinence from concurrent stimulant and opioid use compared with control conditions (mean difference=1.42 wk, 95% CI: 0.77-2.08; I²=50%). Participants receiving contingency management were more likely to submit combined stimulant-opioid-negative urine samples (odds ratio=2.46, 95% CI: 1.96-3.10; I2=0%). Overall treatment retention did not differ between groups, though subgroup analyses suggested improved retention among participants not receiving medication for opioid use disorder.
conclusionsContingency management improves abstinence outcomes among individuals with stimulant-opioid co-use across treatment settings. The absence of fentanyl-specific data highlights an urgent need for research addressing treatment strategies in the context of the evolving synthetic opioid epidemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.